Pharmacodynamics & Pharmacokinetics: PI and PIL considerations
4
Pharmacodynamics & Pharmacokinetics: Pharmacodynamics & Pharmacokinetics: PI and PIL considerations PI and PIL considerations Douglas W Oliver School of Pharmacy / Unit for Drug Research & Development SAAPRA 16 November 2012
description
Pharmacodynamics & Pharmacokinetics: PI and PIL considerations. Douglas W Oliver School of Pharmacy / Unit for Drug Research & Development. SAAPRA 16 November 2012. Presentation. Introduction: Drug Discovery Research Background: PK/PD Pharmacodynamics (CTD Modules 4&5) Pharmacokinetics - PowerPoint PPT Presentation
Transcript of Pharmacodynamics & Pharmacokinetics: PI and PIL considerations
![Page 1: Pharmacodynamics & Pharmacokinetics: PI and PIL considerations](https://reader033.fdocuments.net/reader033/viewer/2022050910/56815e08550346895dcc5ded/html5/thumbnails/1.jpg)
Pharmacodynamics & Pharmacokinetics:Pharmacodynamics & Pharmacokinetics:PI and PIL considerationsPI and PIL considerations
Douglas W OliverSchool of Pharmacy / Unit for Drug Research &
Development
SAAPRA 16 November 2012
![Page 2: Pharmacodynamics & Pharmacokinetics: PI and PIL considerations](https://reader033.fdocuments.net/reader033/viewer/2022050910/56815e08550346895dcc5ded/html5/thumbnails/2.jpg)
Presentation
• Introduction: – Drug Discovery Research
• Background: PK/PD• Pharmacodynamics
– (CTD Modules 4&5)• Pharmacokinetics
– (CTD Modules 4&5)• Specific Considerations• MCC
– Regulatory Framework• Additional Information• Conclusion
![Page 3: Pharmacodynamics & Pharmacokinetics: PI and PIL considerations](https://reader033.fdocuments.net/reader033/viewer/2022050910/56815e08550346895dcc5ded/html5/thumbnails/3.jpg)
INTRODUCTION AND
BACKGROUND
![Page 4: Pharmacodynamics & Pharmacokinetics: PI and PIL considerations](https://reader033.fdocuments.net/reader033/viewer/2022050910/56815e08550346895dcc5ded/html5/thumbnails/4.jpg)
The human
4